semaglutide and insulin resistance From single to triple agonists — the new era of pharmacological weight loss. ➝ Tirzepatide ➝ Retatrutide Satiety. sensitivity. Energy expenditure. Science is finally attacking obesity from multiple hormonal angles ESC 2025: evidence of semaglutide

Retatrutide is an investigational triple receptor agonist being studied for its potential role in weight management by influencing appetite, metabolism and energy balance

It is not intended to diagnose, treat, cure or prevent any disease, and no therapeutic, weight-management or metabolic-health claims are made or implied

For a vial with 20 draws, you lose approximately 0.14-0.24mL to dead volume

Trust us for exceptional support and comprehensive care throughout your treatment journey

The majority of these unregulated peptides have only been tested on animals, not humans, meaning they are not considered safe or effective